In Clinical Studies, COAGADEX Was Proven Effective for Perioperative Treatment
COAGADEX for Prevention of Bleeding During or After Surgery1,2
(in 3 subjects with moderate or severe factor X deficiency)
Safety of COAGADEX in subjects undergoing surgery
- In Study TEN03 (Escobar), the most common adverse events (AEs), each reported on 3 occasions, were constipation and dyspepsia; all other AEs were reported on ≤2 occasions. No AE was considered related to treatment with COAGADEX. Two serious AEs were reported (tooth abscess predating surgical procedure; hospitalization due to bleeding following a complex procedure requiring intravenous anesthesia and intubation to extract 2 teeth). Neither serious AE was considered related to COAGADEX.1
- In Study TEN06 (Norton poster), AEs reported from two patients were anemia, small intestinal obstruction, procedural pain, tachycardia, migraine, and nausea; all were considered unlikely related or unrelated to COAGADEX. One serious AE of intestinal obstruction of severe intensity was reported in one patient; the event resolved and was considered unrelated to COAGADEX. No deaths occurred and no new safety signals were identified.2,3
- No thrombotic events or other evidence of thrombogenicity were reported
- All inhibitor results were negative
- No viral seroconversions were observed
Escobar M, et al. Haemophilia. 2016;22:713-720.
Perioperative management of bleeding in patients with mild to severe hereditary factor X deficiency (Study TEN03).
A pooled analysis of five surgical patients aged 14-59 years with severe, moderate, or mild factor X deficiency from two similarly designed prospective, open-label, multicenter, non-randomized, phase III studies of COAGADEX in the treatment of factor X deficiency. Patients were given a loading dose before the procedure to raise factor X level to 70-90 IU/dL. Doses after surgery were given to maintain factor X level above 50 IU/dL. The primary endpoint was the investigators’ assessment of efficacy of perioperative treatment in prevention of bleeding.
Norton M, Wolford E. Poster presented at Thrombosis & Hemostasis Summit of North America 2022. August 16-18, 2022; Chicago, IL.
Perioperative management of patients with severe hereditary factor X deficiency undergoing major surgery (Study TEN06).
Noninterventional, multicenter, postmarketing registry study of three patients with moderate or severe factor X deficiency requiring major surgery and perioperative management with COAGADEX. Patients were treated with one preoperative dose of COAGADEX at a dose according to the product labeling; additional postoperative doses were permitted to maintain perisurgical hemostasis at the investigators discretion. The primary endpoint was the investigators’ assessment of efficacy of perioperative treatment in prevention of bleeding.
References: 1. Escobar M, et al. Haemophilia. 2016;22:713-720. 2. Norton M, Wolford E. Poster presented at Thrombosis & Hemostasis Summit of North America 2022. August 16-18, 2022; Chicago, IL. 3. Data on File, TEN06 Clinical Study Report.
Indications and Usage for COAGADEX
COAGADEX, a plasma-derived blood coagulation factor X concentrate, is indicated in adults and children with hereditary factor X deficiency for:
- Routine prophylaxis to reduce the frequency of bleeding episodes
- On-demand treatment and control of bleeding episodes
- Perioperative management of bleeding in patients with mild, moderate and severe hereditary factor X deficiency
Contraindication for COAGADEX
COAGADEX is contraindicated in patients who have had life-threatening hypersensitivity reactions to COAGADEX.
Important Safety Information for COAGADEX
Allergic type hypersensitivity reactions, including anaphylaxis, are possible with COAGADEX. If symptoms occur, patients should discontinue use of the product immediately, contact their physician, and administer appropriate treatment.
The formation of neutralizing antibodies (inhibitors) to factor X is a possible complication in the management of individuals with factor X deficiency. Carefully monitor patients taking COAGADEX for the development of inhibitors by appropriate clinical observations and laboratory tests.
COAGADEX is made from human plasma and may contain infectious agents, e.g. viruses, the variant Creutzfeldt-Jakob disease (vCJD) agent and, theoretically, the Creutzfeldt-Jakob disease (CJD) agent. No cases of transmission of viral diseases, vCJD or CJD, have been associated with the use of COAGADEX.
In clinical studies, the most common adverse reactions (frequency ≥5% of subjects) with COAGADEX were infusion site erythema, infusion site pain, fatigue and back pain.